Pidilizumab in the treatment of diffuse large B-cell lymphoma

被引：28

作者：

Bryan, Locke J. ^{[1
]}

Gordon, Leo I. ^{[1
]}

机构：

[1] Northwestern Univ, Div Hematol Oncol, Chicago, IL 60611 USA

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2014年 / 14卷 / 09期

关键词：

diffuse large B-cell lymphoma; monoclonal antibody; non-Hodgkin lymphoma; programmed death-1; pidilizumab; PROGRAMMED DEATH-1; MONOCLONAL-ANTIBODY; T-CELLS; PD-1; EXPRESSION; BLOCKADE; TRANSPLANTATION; LYMPHOCYTES; REGRESSION; TOLERANCE;

D O I：

10.1517/14712598.2014.942637

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 [微生物学]; 090105 [作物生产系统与生态工程];

摘要：

Introduction: The programmed death-1 (PD-1) immune checkpoint pathway is an emerging target in the treatment of hematologic malignancies. Pidilizumab is an mAb that binds to PD-1 and is a safe and well-tolerated therapy. Recent data have shown clinical activity utilizing this strategy in diffuse large B-cell lymphoma (DLBCL). Areas covered: The role of PD-1 expression in hematologic malignancies is explored. Recent clinical trials including the results of a Phase I trial in hematologic malignancies and a Phase II trial of pidilizumab following autologous hematopoietic stem-cell transplant (AHSCT) are reviewed. Expert opinion: We review data that suggest that PD-1 is a promising target in the treatment and management of DLBCL. Changes in immune subsets following administration of pidilizumab are felt to represent on-target responses. The improvement in progression-free survival (PFS) following AHSCT supports a response to therapy. Importantly, the improvement in PFS for patients with positive FDG-PET/CT following AHSCT indicating residual disease further supports direct activity of pidilizumab in DLBCL.

引用

页码：1361 / 1368

页数：8

共 28 条

[1]

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].

Alizadeh, AA ;

Eisen, MB ;

Davis, RE ;

Ma, C ;

Lossos, IS ;

Rosenwald, A ;

Boldrick, JG ;

Sabet, H ;

Tran, T ;

Yu, X ;

Powell, JI ;

Yang, LM ;

Marti, GE ;

Moore, T ;

Hudson, J ;

Lu, LS ;

Lewis, DB ;

Tibshirani, R ;

Sherlock, G ;

Chan, WC ;

Greiner, TC ;

Weisenburger, DD ;

Armitage, JO ;

Warnke, R ;

Levy, R ;

Wilson, W ;

Grever, MR ;

Byrd, JC ;

Botstein, D ;

Brown, PO ;

Staudt, LM .

NATURE, 2000, 403 (6769) :503-511

[2]

Programmed Death Ligand 1 Is Expressed by Non-Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells [J].

Andorsky, David J. ;

Yamada, Reiko E. ;

Said, Jonathan ;

Pinkus, Geraldine S. ;

Betting, David J. ;

Timmerman, John M. .

CLINICAL CANCER RESEARCH, 2011, 17 (13) :4232-4244

[3]

Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial [J].

Armand, Philippe ;

Nagler, Arnon ;

Weller, Edie A. ;

Devine, Steven M. ;

Avigan, David E. ;

Chen, Yi-Bin ;

Kaminski, Mark S. ;

Holland, H. Kent ;

Winter, Jane N. ;

Mason, James R. ;

Fay, Joseph W. ;

Rizzieri, David A. ;

Hosing, Chitra M. ;

Ball, Edward D. ;

Uberti, Joseph P. ;

Lazarus, Hillard M. ;

Mapara, Markus Y. ;

Gregory, Stephanie A. ;

Timmerman, John M. ;

Andorsky, David ;

Or, Reuven ;

Waller, Edmund K. ;

Rotem-Yehudar, Rinat ;

Gordon, Leo I. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (33) :4199-4206

[4]

Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era [J].

Armand, Philippe ;

Welch, Sarah ;

Kim, Haesook T. ;

LaCasce, Ann S. ;

Jacobsen, Eric D. ;

Davids, Matthew S. ;

Jacobson, Caron ;

Fisher, David C. ;

Brown, Jennifer R. ;

Coughlin, Erin ;

Freedman, Arnold S. ;

Chen, Yi-Bin .

BRITISH JOURNAL OF HAEMATOLOGY, 2013, 160 (05) :608-617

[5]

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies [J].

Berger, Raanan ;

Rotem-Yehudar, Rinat ;

Slama, Gideon ;

Landes, Shimon ;

Kneller, Abraham ;

Leiba, Merav ;

Koren-Michowitz, Maya ;

Shimoni, Avichai ;

Nagler, Arnon .

CLINICAL CANCER RESEARCH, 2008, 14 (10) :3044-3051

[6]

High Numbers of Tumor-Infiltrating Programmed Cell Death 1-Positive Regulatory Lymphocytes Are Associated With Improved Overall Survival in Follicular Lymphoma [J].

Carreras, Joaquim ;

Lopez-Guillermo, Armando ;

Roncador, Giovanna ;

Villamor, Neus ;

Colomo, Lluis ;

Martinez, Antonio ;

Hamoudi, Rifat ;

Howat, William J. ;

Montserrat, Emili ;

Campo, Elias .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1470-1476

[7]

Chan WC, 1997, BLOOD, V89, P3909

[8]

PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies [J].

Chen, Benjamin J. ;

Chapuy, Bjoern ;

Jing Ouyang ;

Sun, Heather H. ;

Roemer, Margaretha G. M. ;

Xu, Mina L. ;

Yu, Hongbo ;

Fletcher, Christopher D. M. ;

Freeman, Gordon J. ;

Shipp, Margaret A. ;

Rodig, Scott J. .

CLINICAL CANCER RESEARCH, 2013, 19 (13) :3462-3473

[9]

Nodular lymphocyte predominant Hodgkin lymphoma and diffuse large B-cell lymphoma: a study of six cases concurrently involving the same site [J].

Cotta, Claudiu V. ;

Coleman, Joshua F. ;

Li, Shiyong ;

Hsi, Eric D. .

HISTOPATHOLOGY, 2011, 59 (06) :1194-1203

[10]

Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma [J].

Dorfman, DM ;

Brown, JA ;

Shahsafaei, A ;

Freeman, GJ .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2006, 30 (07) :802-810

← 1 2 3 →